Termination of Temporary Deferment of Activities Relating to Biologics Submissions and Notice of New Mailing Address

Riepilogo

The Food and Drug Administration (FDA) is announcing the new address for submissions and identifying the exact period which action on pending submissions was temporarily deferred. In a notice published in the Federal Register of January 13, 1993 (58 FR 4173), FDA announced that the Document Control Center of the Center for Biologics Evaluation and Research (CBER) moved from various locations in Rockville and Bethesda, MD to the Woodmont Office Center, 1401 Rockville Pike, Rockville, MD. During the period required for relocation of the office, which began on January 6, 1993, and ended on January 22, 1993, the agency temporarily deferred submissions subject to CBER review and approval, and the review period, if any, on pending submissions was suspended. FDA also requested that sponsors voluntarily refrain from filing submission during this period. Normal operations resumed on January 25, 1993. FDA is also announcing the installation of automated systems to make information available to the public and to help callers identify the new telephone numbers of CBER staff involved in review activities. ADDRESSES: All submissions for CBER review should now be addressed to the new location: Fo